Literature DB >> 2403515

Hemodynamic management in pulmonary embolism and acute hypoxemic respiratory failure.

R M Prewitt1.   

Abstract

Management of patients with the adult respiratory distress syndrome should be directed toward maintaining adequate cardiac output and tissue oxygenation without exacerbating pulmonary edema. The aim of therapy should be to maintain low left ventricular filling pressure, which will tend to decrease the rate of edema formation. If cardiac output is low or decreases as a function of therapy, flow may be increased with inotropic agents. When a marked decline in cardiac output complicates pulmonary embolism, norepinephrine may be an excellent drug for at least short-term maintenance of hemodynamic stability. When a moderate decrease in cardiac output complicates an increase in right ventricular afterload, isoproterenol or dobutamine may be used to increase flow. Rapid administration of recombinant tissue plasminogen activator may be the treatment of choice of pulmonary thromboembolism associated with a low output state.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403515

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

1.  [High risk pulmonary embolism. Case report of a successful embolectomy].

Authors:  J Kalbhenn; T Loop; C A Stahl
Journal:  Anaesthesist       Date:  2011-11       Impact factor: 1.041

Review 2.  Catecholamines in critical care. The commonly used catecholamines: receptor and clinical profile, indications and dosages.

Authors:  F W Santman
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

3.  Pulmonary embolism, part II: Management.

Authors:  Jan Bĕlohlávek; Vladimír Dytrych; Aleš Linhart
Journal:  Exp Clin Cardiol       Date:  2013

4.  Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension.

Authors:  C D Vizza; G D Rocca; A D Roma; C Iacoboni; F Pierconti; F Venuta; E Rendina; G Schmid; P Pietropaoli; F Fedele
Journal:  Crit Care       Date:  2001-10-09       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.